Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis

Reports

4

Domains carrying it

4

First reported

28 August 2026

Latest report

4 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 28 August 2026Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositisbiospace.com
2. 29 August 2026FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant's Biz Strategyramaonhealthcare.com
3. 4 September 2026Roivant Sciences (ROIV) Wins FDA Approval For LISRAYA, Is The Upside Already Priced In?simplywall.st

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For ...4 reports · 4 domains · 10 August 2026
• Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced ...2 reports · 2 domains · 17 August 2026
• Dr Reddy's wins FDA nod for rituximab biosimilar5 reports · 5 domains · 14 August 2026
• Labcorp's advanced melanoma CDx secures FDA approval3 reports · 3 domains · 10 August 2026
• FDA sNDA Submission Is Planned for Selinexor Plus Ruxolitinib in Myelofibrosis2 reports · 2 domains · 1 August 2026
• Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...2 reports · 2 domains · 31 August 2026

◆ Share

◆ Evidence

4 reports · 4 domains

• Roivant Sciences (ROIV) Wins FDA Approval For LISRAYA, Is The Upside Already Priced In?simplywall.st · 4 September 2026
• Roivant Sciences posts presentation on FDA approval and launches LISRAYA commercially ...tradingview.com · 29 August 2026
• FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant's Biz Strategyramaonhealthcare.com · 29 August 2026
• Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositisbiospace.com · 28 August 2026